玛仕度肽 Mazdutide
理化性质
CAS 号
2259884-03-0
作用与功效
作用机制与靶点
GLP-1 / 胰高血糖素 (GCGR) 双重激动剂
功效说明
强效降低体重的同时，GCGR 成分能直接提升基础能量消耗，显著改善肝脏脂质代谢与胰岛素抵抗，针对性减少内脏脂肪。
英文详细资料 / Details (EN)
英文简介 / Overview (EN)
Mazdutide (also known as IBI362 or LY3305677) is a dual agonist of the GLP-1 receptor and glucagon receptor. It is an analog of oxyntomodulin (OXM). The drug is developed by Eli Lilly and Innovent Biologics. and is currently in multiple Phase III studies. In May 2025, a result of Phase III study has shown that once-weekly mazdutide led to clinically relevant reductions in body weight in Chinese adults with overweight or obesity.
In June 2025, Mazdutide injection is approved for marketing in China.
Source: English Wikipedia, "Mazdutide".
强效降低体重的同时，GCGR 成分能直接提升基础能量消耗，显著改善肝脏脂质代谢与胰岛素抵抗，针对性减少内脏脂肪。